Skip to main content

Table 1 Summary of included trials comparing bevacizumab with interferon (Bev + IFN), sunitinib, and pazopanib to interferon alone (IFN) or one another as first-line therapy for patients with clear cell renal cell carcinoma

From: Comparative effectiveness of approved first-line anti-angiogenic and molecularly targeted therapeutic agents in the treatment of good and intermediate risk metastatic clear cell renal cell carcinoma

Trial Treatment arms (n) Overall survival Progression-free survival Response
   Mediana HR (95% CI) Mediana HR (95% CI) Percent OR (95% CI)
Rini et al. (2008; 2013) [15, 16] Bev + IFNb,c (n = 369) 18.3 0.86 (0.73-1.01) 8.5 0.71 (0.61-0.83) 26% 2.27 (1.51-3.42)
IFNc (n = 363) 17.4 5.2 13%
Escudier et al. (2007; 2010) [17, 18] Bev + IFNb,c (n = 327) 23.3 0.86 (0.72-1.04) 10.2 0.61 (0.51-0.73) 31%f 3.11 (2.04-4.74)
IFNc (n = 322) 21.3 5.4 13%f
Motzer et al. (2013) [19] Pazopanibd (n = 557) 28.4 0.91 (0.76-1.08) 8.4 1.05 (0.90-1.22) 31% 1.35 (1.03-1.75)
Sunitinibe (n = 553) 29.3 9.5 25%
Motzer et al. (2007; 2009) [14] Sunitinibe (n = 375) 26.4 0.82 (0.67-1.00) 11 0.54 (0.45-0.64) 47% 6.33 (4.37-9.15)
  IFNc (n = 375) 21.8   5   12%  
  1. amonths.
  2. bbevucizumab 10 mg/kg every 2 weeks.
  3. cinterferon alfa 9 million units subcutaneously three times weekly.
  4. dpazopanib 800 mg once daily.
  5. esunitinib 50 mg once daily for 4 weeks, followed by 2 weeks off.
  6. fdenominator for Bev + IFN 306, denominator for IFN + Placebo 289.